南新制药：2025年亏损1.37亿元

Core Viewpoint - The company reported a significant decline in revenue and increased losses for the year 2025, attributed to intensified market competition and reduced demand due to fewer flu cases in the domestic market [2][3]. Financial Performance - The company achieved a revenue of 142 million yuan in 2025, a year-on-year decrease of 46.09% [2]. - The net profit attributable to shareholders was a loss of 137 million yuan, compared to a loss of 357 million yuan in the previous year [2]. - The non-recurring net profit also showed a loss of 139 million yuan, slightly better than the loss of 359 million yuan in the previous year [2]. - The basic earnings per share were -0.5006 yuan, with a weighted average return on equity of -15.84%, an increase of 16.03 percentage points from the previous year [2][10]. Market Conditions - The decline in revenue and gross margin was influenced by the ongoing implementation of centralized procurement policies in the domestic pharmaceutical industry and the introduction of competing products [3]. - The company maintained a high level of R&D investment to sustain its core competitiveness despite the losses incurred during the reporting period [3].